Literature DB >> 8852035

[The combination therapy with vinca-alkaloid slow infusion and cholchicine was effective to refractory idiopathic thrombocytopenic purpura. The patient could receive femoral head replacement in safety].

M Nezu1, H Oh, R Cho, H Sato, T Ikegami, A Yokota, C Nakaseko, M Nishimura, Y Matsuura, S Morio, K Hiruma, H Nakamura, T Asai.   

Abstract

A 46-year-old man with idiopathic thrombocytopenic purpura (ITP) refractory to corticosteroid, splenectomy and other drugs was admitted to our hospital in August, 1994, because of aseptic necrosis of the right femoral head. Although high-dose intravenous gamma-globulin was ineffective, the platelet count was increased within two weeks by the combination therapy that consisted of 0.02 mg/kg vincristine alternating with 0.1 mg/kg vinblastine by slow infusion at a 1-week interval, and oral 1.5 mg/day colchicine. He subsequently underwent the femoral head replacement. This combination therapy seems to be useful for refractory ITP in preparation for surgery.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852035

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  4 in total

1.  Perioperative care of a patient with refractory idiopathic thrombocytopenic purpura undergoing total knee arthroplasty.

Authors:  Rohit Singhal; Veera Gudimetla; Andrew Stewart; Karen L Luscombe; Charalambos P Charalambous
Journal:  Knee Surg Relat Res       Date:  2012-11-29

2.  THA in Patients with Idiopathic Thrombocytopenic Purpura (ITP): A Case Report.

Authors:  Koji Suzuki; Sadaomi Kawachi; Hideki Nanke; Takayoshi Ito
Journal:  J Rural Med       Date:  2011-12-17

3.  Outcomes of total hip arthroplasty in patients with primary immune thrombocytopenia.

Authors:  Seung-Jae Lim; Ingwon Yeo; Chan-Woo Park; Young-Wan Moon; Youn-Soo Park
Journal:  BMC Musculoskelet Disord       Date:  2015-10-05       Impact factor: 2.362

Review 4.  Multiple total hip arthroplasties in refractory immune thrombocytopenic purpura: A case report and literature review.

Authors:  Yilun Tang; Yan Xu; Zhibin Shi; Xiaorong Ma; Lihong Fan; Kunzheng Wang; Xiaoqian Dang
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.